Recent research presented at the ESMO Congress 2024 confirms that breastfeeding after breast cancer treatment is safe for women with germline BRCA mutations. Two major international studies indicate that breastfeeding does not increase the risk of cancer recurrence or the development of new breast cancers in these patients.
Key Findings
Safety for BRCA Mutation Carriers: The study followed nearly 5,000 young women with BRCA mutations who had survived breast cancer. Of the 474 who gave birth, 25% breastfed. After a median follow-up of seven years, there was no increased risk of breast cancer recurrence or new cases among those who breastfed compared to those who did not.
Broader Applicability: A second study focusing on women with hormone receptor-positive early breast cancer found similar safety outcomes, reinforcing that breastfeeding does not pose additional risks.
Changing Perspectives: Dr. Fedro Alessandro Peccatori and other experts emphasize the importance of considering breastfeeding as a viable option for breast cancer survivors. This research helps to dispel previous concerns about breastfeeding and hormonal changes related to breast cancer treatment.
Future Directions: Dr. Maria Alice Franzoi highlights the need for ongoing research to further validate these findings and incorporate them into survivorship care planning. This will help in providing comprehensive guidance to women considering pregnancy and breastfeeding post-treatment.
Conclusion
These studies offer reassurance that breastfeeding is a safe choice for breast cancer survivors, including those with BRCA mutations, and support the need for continued focus on reproductive options and survivorship care in cancer recovery.
